Skip to main content
Top
Published in: Diabetologia 6/2021

Open Access 01-06-2021 | Insulins | Article

The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes

Authors: Andreas Höhn, Anita Jeyam, Thomas M. Caparrotta, Stuart J. McGurnaghan, Joseph E. O’Reilly, Luke A. K. Blackbourn, Rory J. McCrimmon, Graham P. Leese, John A. McKnight, Brian Kennon, Robert S. Lindsay, Naveed Sattar, Sarah H. Wild, Paul M. McKeigue, Helen M. Colhoun, on behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group

Published in: Diabetologia | Issue 6/2021

Login to get access

Abstract

Aims/hypothesis

The aim of this work was to map the number of prescribed drugs over age, sex and area-based socioeconomic deprivation, and to examine the association between the number of drugs and particular high-risk drug classes with adverse health outcomes among a national cohort of individuals with type 1 diabetes.

Methods

Utilising linked healthcare records from the population-based diabetes register of Scotland, we identified 28,245 individuals with a diagnosis of type 1 diabetes on 1 January 2017. For this population, we obtained information on health status, predominantly reflecting diabetes-related complications, and information on the total number of drugs and particular high-risk drug classes prescribed. We then studied the association of these baseline-level features with hospital admissions for falls, diabetic ketoacidosis (DKA), and hypoglycaemia or death within the subsequent year using multivariate Cox proportional hazards models.

Results

Not considering insulin and treatment for hypoglycaemia, the mean number of prescribed drugs was 4.00 (SD 4.35). The proportion of individuals being prescribed five or more drugs at baseline consistently increased with age (proportion [95% CI]: 0–19 years 2.04% [1.60, 2.49]; 40–49 years 28.50% [27.08, 29.93]; 80+ years 76.04% [67.73, 84.84]). Controlling for age, sex, area-based socioeconomic deprivation and health status, each additional drug at baseline was associated with an increase in the hazard for hospitalisation for falls, hypoglycaemia and death but not for DKA admissions (HR [95% CI]: falls 1.03 [1.01, 1.06]; DKA 1.01 [1.00, 1.03]; hypoglycaemia 1.05 [1.02, 1.07]; death 1.04 [1.02, 1.06]). We found a number of drug classes to be associated with an increased hazard of one or more of these adverse health outcomes, including antithrombotic/anticoagulant agents, corticosteroids, opioids, antiepileptics, antipsychotics, hypnotics and sedatives, and antidepressants.

Conclusions

Polypharmacy is common among the Scottish population with type 1 diabetes and is strongly patterned by sociodemographic factors. The number of prescribed drugs and the prescription of particular high-risk drug classes are strong markers of an increased risk of adverse health outcomes, including acute complications of diabetes.

Graphical abstract

Appendix
Available only for authorised users
Literature
7.
go back to reference Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE (2017) What is polypharmacy? A systematic review of definitions. BMC Geriatr 17(1):230CrossRef Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE (2017) What is polypharmacy? A systematic review of definitions. BMC Geriatr 17(1):230CrossRef
9.
go back to reference Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T (2015) The rising tide of polypharmacy and drug-drug interactions: Population database analysis 1995–2010. BMC Med 13(1):74CrossRef Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T (2015) The rising tide of polypharmacy and drug-drug interactions: Population database analysis 1995–2010. BMC Med 13(1):74CrossRef
10.
go back to reference Morin L, Johnell K, Laroche M-L, Fastbom J, Wastesson JW (2018) The epidemiology of polypharmacy in older adults: Register-based prospective cohort study. Clin Epidemiol 10:289–298CrossRef Morin L, Johnell K, Laroche M-L, Fastbom J, Wastesson JW (2018) The epidemiology of polypharmacy in older adults: Register-based prospective cohort study. Clin Epidemiol 10:289–298CrossRef
22.
go back to reference Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC study 30-year follow-up. Diabetes Care 39(5):686–693. https://doi.org/10.2337/dc15-1990CrossRef Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC study 30-year follow-up. Diabetes Care 39(5):686–693. https://​doi.​org/​10.​2337/​dc15-1990CrossRef
38.
go back to reference Oksuzyan A, Sauer T, Gampe J et al (2019) Is who you ask important? Concordance between survey and registry data on medication use among self- and proxy-respondents in the longitudinal study of aging Danish Twins and the Danish 1905-Cohort Study. J Gerontol Ser A 74(5):742–747. https://doi.org/10.1093/gerona/gly104CrossRef Oksuzyan A, Sauer T, Gampe J et al (2019) Is who you ask important? Concordance between survey and registry data on medication use among self- and proxy-respondents in the longitudinal study of aging Danish Twins and the Danish 1905-Cohort Study. J Gerontol Ser A 74(5):742–747. https://​doi.​org/​10.​1093/​gerona/​gly104CrossRef
41.
45.
go back to reference Huiskes VJB, Burger DM, van den Ende CHM, van den Bemt BJF (2017) Effectiveness of medication review: A systematic review and meta-analysis of randomized controlled trials. BMC Fam Pract 18(1):5CrossRef Huiskes VJB, Burger DM, van den Ende CHM, van den Bemt BJF (2017) Effectiveness of medication review: A systematic review and meta-analysis of randomized controlled trials. BMC Fam Pract 18(1):5CrossRef
Metadata
Title
The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes
Authors
Andreas Höhn
Anita Jeyam
Thomas M. Caparrotta
Stuart J. McGurnaghan
Joseph E. O’Reilly
Luke A. K. Blackbourn
Rory J. McCrimmon
Graham P. Leese
John A. McKnight
Brian Kennon
Robert S. Lindsay
Naveed Sattar
Sarah H. Wild
Paul M. McKeigue
Helen M. Colhoun
on behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group
Publication date
01-06-2021
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 6/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-021-05394-7

Other articles of this Issue 6/2021

Diabetologia 6/2021 Go to the issue